Lion Biotechnologies announces positive data from a TIL-Ipilimumab combination study
Lion Biotechnologies announced that researchers from Moffitt Cancer Center reported positive results from a pilot trial of TIL and ipilimumab in patients with metastatic melanoma. Of the 12 patients enrolled in the trial, 11 went on to receive their autologous TIL. March 30, 2015